Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals is a biopharmaceutical royalty company that acquires, finances, and licenses rights to high-value medicines rather than developing drugs itself. It generates revenue mainly from royalties on partner product sales, plus Captisol material sales and license, milestone, and other contract income.

27,9 %

46,4 %

+60,4 %

22.23

21.98

— Ligand Pharmaceuticals Incorporated
%
Royalty assets75% Economic rights to sales of partnered biopharmaceutical products, including commercial and late-stage programs.
Captisol15% Infrastructure-light cyclodextrin technology used to improve drug solubility and stability, generating material sales and royalties.
Technology licensing and milestones10% License fees, development, regulatory, and sales-based milestone payments from partner programs.

Ligand's customers are primarily biopharmaceutical companies that need capital, technology, or royalty monetization to...

  • Biopharmaceutical development partnersprimary

    Mid- to late-stage drug developers that receive financing or technology support in exchange for royalties or economic rights.

  • Commercial pharmaceutical partnersprimary

    Companies marketing approved products that generate royalty revenue for Ligand based on partner sales.

  • Technology licenseessecondary

    Partners using Captisol or NITRICIL to improve formulation, solubility, or dosing of medicines.

  • Royalty asset sellers and asset ownerssecondary

    Counterparties that sell royalty interests or embedded royalty rights to Ligand for upfront capital.

Ligand is headquartered in the United States and its revenue is generated primarily through global partner product...

  • •Headquartered in the United States
  • •Revenue depends on global partner sales of licensed medicines
  • •Royalty exposure spans U.S., Europe, and other major pharma markets
  • •Captisol and partner programs create cross-border regulatory exposure
  • •Limited owned manufacturing footprint reduces fixed geographic assets

Ligand is focused on disciplined capital deployment into differentiated royalty streams and on expanding its portfolio...

01
Expand royalty portfoliomedium-term

More assets reduce concentration risk and increase recurring cash flow sources.

02
Monetize platform technologiesmedium-term

Captisol and NITRICIL can generate royalties without heavy infrastructure investment.

03
Keep operating model leanshort-term

Low overhead supports high margins and makes royalty cash flows more valuable.

Ligand's cash flows depend on partner product sales, partner execution, and the durability of royalty assets, so...

high

Dependence on partner product sales

Royalty revenue is tied to commercial performance of third-party medicines, not Ligand-controlled operations.

Scope
Kyprolis, Filspari, Rylaze, Vaxneuvance and other partnered products
Materiality
high
high

Captisol sole-supplier concentration

A supply interruption could disrupt material sales and related revenue streams.

Scope
Captisol platform technology
Materiality
high
high

Partner development and regulatory failure

Late-stage programs can fail or be delayed, reducing milestone and royalty potential.

Scope
Development-stage financing and licensed programs
Materiality
high
medium

Partner insolvency or strategic shift

Counterparties may deprioritize programs or be unable to fund commercialization.

Scope
Collaboration partners and royalty counterparties
Materiality
medium
medium

Pelthos investment exposure

Ligand retains equity and preferred stock exposure to a recently carved-out business.

Scope
Pelthos Therapeutics ownership and related investments
Materiality
medium
Financial royalty asset income recognition
Affects royalty revenue timing and volatility
Non-accrual treatment for developmental assets
Can delay revenue recognition until cash flows become more predictable
Milestone and license revenue
Creates quarter-to-quarter revenue lumpiness
Impairment of finite-lived intangibles
Can materially affect operating income
Fair value adjustments on partner derivatives
Can add non-cash volatility to earnings

LIGAND PHARMACEUTICALS INC

LGND · Pharmaceutical Preparations

Cinclus Pharma Holding

CINPHA.ST · Health Care

Citius Pharmaceuticals, Inc.

CTXR · Pharmaceutical Preparations

ALIGN TECHNOLOGY INC

ALGN · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Unicycive Therapeutics, Inc.

UNCY · Pharmaceutical Preparations

MANNKIND CORP

MNKD · Pharmaceutical Preparations

: 28/04/2026